Literature DB >> 2542039

5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation.

H E Connor1, W Feniuk, P P Humphrey.   

Abstract

5-Hydroxytryptamine (5-HT) caused contractions of human isolated epicardial coronary arteries which were markedly antagonised by ketanserin (10 nM-1 microM). The antagonism was not competitive. The selective 5-HT1-like receptor agonist, GR43175, caused only small, ketanserin-resistant contractions. These results suggest that the predominant contractile effect of 5-HT in human isolated large coronary arteries is mediated via 5-HT2 receptors but that, in addition, 5-HT1-like receptors contribute to some degree to this response in vitro.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2542039     DOI： 10.1016/0014-2999(89)90184-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  36 in total

1.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  Coronary vasospasm and sumatriptan.

Authors:  B H Stricker
Journal:  BMJ       Date:  1992-07-11

3.  The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects.

Authors:  Peer Tfelt-Hansen; Kaj Seidelin; Michael Stepanavage; Christopher Lines
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

4.  Effect of the thromboxane A2-mimetic U46619 on 5-HT1-like and 5-HT2 receptor-mediated contraction of the rabbit isolated femoral artery.

Authors:  S J MacLennan; G R Martin
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

5.  Contractions to 5-hydroxytryptamine in human coronary artery and human saphenous vein.

Authors:  M Borton; M Neligan; F Wood; P Dervan; K Goggins; J R Docherty
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

6.  Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries.

Authors:  Christopher M H Newman; Ian Starkey; Nigel Buller; Ricardo Seabra-Gomes; Simon Kirby; Jayasena Hettiarachchi; David Cumberland; William S Hillis
Journal:  Eur J Clin Pharmacol       Date:  2005-09-08       Impact factor: 2.953

7.  A case of myocardial infarction with sumatriptan use.

Authors:  E Erbilen; H Ozhan; R Akdemir; M Yazici
Journal:  Pediatr Cardiol       Date:  2005 Jul-Aug       Impact factor: 1.655

8.  Mechanism of 5-hydroxytryptamine-induced coronary vasodilation assessed by direct detection of nitric oxide production in guinea-pig isolated heart.

Authors:  A J Ellwood; M J Curtis
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

9.  Adverse reactions attributed to sumatriptan. A postmarketing study in general practice.

Authors:  J P Ottervanger; T B van Witsen; H A Valkenburg; D E Grobbee; B H Stricker
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 10.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.